Article Text

08.36 Profile of patients with rheumatoid arthritis (ra) that are kept with optimised regimen of biological therapies (bt) for a longer term period
  1. Julia Uceda Montañez,
  2. Raquel Hernández Sánchez,
  3. Jose L Marenco de la Fuente
  1. Rheumatology Unit, University Valme Hospital, Seville, Spain


Background and objetives RA is the most common chronic inflammatory arthropathy. About 30% of patients are treated with BT. The optimisation of BT doses in patients in clinical remission is a strategy used in clinical practice.

Primary endpoint: analyse the characteristics of the patients with RA, in follow-up Rheumatology Unit Valme University Hospital, Sevilla, Spain, who remain for a longer period of time in optimisation of BT doses compared to patients in whom they are suspended regime.

Materials and methods Observational, descriptive, longitudinal and retrospective study in a cohort of 32 patients with RA (ACR 1987), which performs treatment with reduced doses of BT.

A description of the baseline characteristics of the patients. These were compared between the group that maintained optimised doses versus the group in which the optimisation regimen had been discontinued.

Result 62.5% women, mean age at diagnosis: 42.6 years. The mean duration of RA at the start of TB was 98.63 months and the time to onset of BT reduction was 160.66 months. 75% was FR positive and 56.7% ACPA positive.

59.4% received etanercept, 21.9% adalimumab, 12.5% infliximab and 6.3% certolizumab.

11 patients discontinued dose reduction. The mean time with reduction of BT was 15.90 months.

Men (83.3%) stay longer in reduced doses than women (55%). Patients with negative ACPA and negative RF remained longer with reduced doses (69.2% and 75% respectively). No differences were observed in DAS28, duration of disease until the first reduction and number of previous BT performed until the reduced biological.

Conclusion The mean time in reduced doses to relapse in patients with end of reduction was 15.90 months.

The drug with the longest time remaining patients with reduced dose in our sample was infliximab. According to the results of our study, male and patients with ACPA and negative FR, remain longer with reduced doses. No differences were found between the two groups when comparing DAS28 prior to reduction of BT, disease duration and number of previous BT used.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.